EP0604624A4 - Multimeric forms of human rhinovirus receptor protein. - Google Patents

Multimeric forms of human rhinovirus receptor protein.

Info

Publication number
EP0604624A4
EP0604624A4 EP93915452A EP93915452A EP0604624A4 EP 0604624 A4 EP0604624 A4 EP 0604624A4 EP 93915452 A EP93915452 A EP 93915452A EP 93915452 A EP93915452 A EP 93915452A EP 0604624 A4 EP0604624 A4 EP 0604624A4
Authority
EP
European Patent Office
Prior art keywords
receptor protein
human rhinovirus
multimeric forms
rhinovirus receptor
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915452A
Other languages
German (de)
French (fr)
Other versions
EP0604624A1 (en
Inventor
Jeffrey M Greve
Alan Mcclelland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of EP0604624A1 publication Critical patent/EP0604624A1/en
Publication of EP0604624A4 publication Critical patent/EP0604624A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/095—Rhinovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP93915452A 1992-06-22 1993-06-22 Multimeric forms of human rhinovirus receptor protein. Withdrawn EP0604624A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90306992A 1992-06-22 1992-06-22
US903069 1992-06-22
PCT/US1993/005972 WO1994000485A1 (en) 1992-06-22 1993-06-22 Multimeric forms of human rhinovirus receptor protein

Publications (2)

Publication Number Publication Date
EP0604624A1 EP0604624A1 (en) 1994-07-06
EP0604624A4 true EP0604624A4 (en) 1997-03-12

Family

ID=25416893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915452A Withdrawn EP0604624A4 (en) 1992-06-22 1993-06-22 Multimeric forms of human rhinovirus receptor protein.

Country Status (10)

Country Link
EP (1) EP0604624A4 (en)
JP (1) JPH06510208A (en)
KR (1) KR950702576A (en)
AU (1) AU675441B2 (en)
CA (1) CA2116109A1 (en)
FI (1) FI946006A0 (en)
HU (1) HUT75827A (en)
NO (1) NO944966L (en)
RU (1) RU94046450A (en)
WO (1) WO1994000485A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (en) 1988-09-01 2000-03-16 Bayer Ag HUMAN RHINOVIRUS RECEPTOR PROTEIN INHIBITING VIRUS INFECTIVITY.
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9520641D0 (en) * 1995-10-10 1995-12-13 Medical Res Council Improvements in or relating to protection against intracellular infection
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
BR112014024398B1 (en) * 2012-03-31 2022-03-08 R-Pharm International, Llc POLYPEPTIDE BINDING HUMAN RANKL, THERAPEUTIC COMPOSITIONS COMPRISING SAID POLYPEPTIDE, ISOLATED NUCLEIC ACID, EXPRESSION VECTOR AND THERAPEUTIC USE OF SAID POLYPEPTIDE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365837A2 (en) * 1988-09-28 1990-05-02 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
EP0387701A1 (en) * 1989-03-09 1990-09-19 Boehringer Ingelheim Pharmaceuticals Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
EP0468257A1 (en) * 1990-07-20 1992-01-29 Bayer Corporation Multimeric form of human rhinovirus receptor protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365837A2 (en) * 1988-09-28 1990-05-02 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
EP0387701A1 (en) * 1989-03-09 1990-09-19 Boehringer Ingelheim Pharmaceuticals Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
EP0468257A1 (en) * 1990-07-20 1992-01-29 Bayer Corporation Multimeric form of human rhinovirus receptor protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREVE J. M. ET AL.,: "Mechanism of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1", J. VIROLOGY, vol. 65, November 1991 (1991-11-01), pages 6015 - 6023, XP000615280 *
MARTIN S. ET AL.,: "Erfolgreiche Blockade von Rhinovirusinfektionen durch ICAM-1-Immunglobulinchimäre in vitro", MEDIZINISCHE KLINIK, vol. 88, no. 4, 15 April 1993 (1993-04-15), pages 193 - 197, XP000615274 *
See also references of WO9400485A1 *

Also Published As

Publication number Publication date
AU675441B2 (en) 1997-02-06
JPH06510208A (en) 1994-11-17
NO944966D0 (en) 1994-12-21
CA2116109A1 (en) 1994-01-06
HUT75827A (en) 1997-05-28
KR950702576A (en) 1995-07-29
AU4543293A (en) 1994-01-24
WO1994000485A1 (en) 1994-01-06
FI946006A (en) 1994-12-21
NO944966L (en) 1994-12-21
RU94046450A (en) 1996-10-10
FI946006A0 (en) 1994-12-21
EP0604624A1 (en) 1994-07-06
HU9403720D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
ZA889033B (en) Vectors and compounds for direct expression of activated human protein c.
EP0605442A4 (en) Recombinant antibodies for human therapy.
FI935175A0 (en) Tyrosine-HER4 human receptor
EP0828751A4 (en) Human neuropeptide receptor
IL106278A0 (en) Bone formation-inducing protein
GB9215540D0 (en) Protein expression system
EP0604624A4 (en) Multimeric forms of human rhinovirus receptor protein.
GB9215541D0 (en) Protein expression system
EP0999848A4 (en) Chimeric proteins for the treatment of diabetes
EP0873409A4 (en) Equine rhinovirus 1 proteins
HUP9901204A3 (en) Novel protein hmw human mp52
PL324822A1 (en) Human protein mp52 arg
ZA896820B (en) Human rhinovirus peptides
IL105549A0 (en) Human glutamate receptor proteins and associated dna compounds
NZ320450A (en) Control of whitefly using optionally substituted chlorophenyls
SG52708A1 (en) Chimeric receptor polypeptides human h13 proteins and uses thereof
AU2444692A (en) Human substance p receptor
GB9215550D0 (en) Protein expression system
AU7174696A (en) Multimeric forms of human rhinovirus receptor protein
AU652567C (en) Multimeric form of human rhinovirus receptor protein
EP0674003A3 (en) Modulatory proteins of human CNS receptors.
EP0787795A4 (en) Variant protein of human dna topoisomerase i
IL105307A0 (en) Serotonin receptor protein and related dna compounds
IE892805L (en) Human rhinovirus receptor protein
GB2297470B (en) An animal hutch

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 19970127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011222